2-((1-(2-(1H-indol-2-yl)acetyl)-4-phenylpiperidin-4-yl)amino)-N-hydroxypyrimidine-5-carboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 2-((1-(2-(1H-indol-2-yl)acetyl)-4-phenylpiperidin-4-yl)amino)-N-hydroxypyrimidine-5-carboxamide
• 英文别名: N-hydroxy-2-[[1-[2-(1H-indol-3-yl)acetyl]-4-phenylpiperidin-4-yl]amino]pyrimidine-5-carboxamide
• 化学式: C₂₆H₂₆N₆O₃
• 分子量: 470.531
• InChiKey: NBHLUEFREQLSRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  123
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  ethyl 2-[[1-[2-(1H-indol-3-yl)acetyl]-4-phenylpiperidin-4-yl]amino]pyrimidine-5-carboxylate 在 羟胺 、 sodium hydroxide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 2.17h， 以10%的产率得到2-((1-(2-(1H-indol-2-yl)acetyl)-4-phenylpiperidin-4-yl)amino)-N-hydroxypyrimidine-5-carboxamide
  参考文献：
  名称：

  PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS

  摘要：

  本文提供了化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与HDAC活性相关的疾病或疾病的方法，特别是涉及HDAC1、HDAC2和/或HDAC6活性的疾病或疾病。本文还提供了抑制神经母细胞瘤细胞迁移、诱导神经母细胞瘤细胞成熟以及改变神经母细胞瘤细胞细胞周期进展的方法，包括向细胞施加HDAC1、HDAC2和/或HDAC6选择性抑制剂或其药用盐的治疗有效量。

  公开号：

  US20150105384A1

文献信息

• INDUCTION OF GATA2 BY HDAC1 AND HDAC2 INHIBITORS
  申请人：ACETYLON PHARMACEUTICALS, INC.

  公开号：US20160137630A1

  公开（公告）日：2016-05-19

  Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with Gata2 deficiency, particularly diseases or disorders that involve any type of HDAC1 and/or HDAC2 expression. Such diseases include acute myeloid leukemia (AML); familial myelodysplastic syndrome (MDS); leukemia; sickle-cell anemia; beta-thalassemia; monocytopenia and mycobacterial infections; dendritic cell, nonocyte, B, and natural killer lymphoid deficiency; Emberger syndrome; asymptomatic neurocognitive impairment; mild neurocognitive disorder; and HIV-associated dementia.

  本文提供了化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗与Gata2缺陷相关的疾病或障碍的方法，特别是涉及任何类型的HDAC1和/或HDAC2表达的疾病或障碍。这些疾病包括急性髓性白血病（AML）；家族性骨髓增生异常综合征（MDS）；白血病；镰形细胞贫血；β-地中海贫血；单核细胞减少和分枝杆菌感染；树突状细胞、非细胞、B和自然杀伤淋巴细胞缺乏；恩伯格综合征；无症状神经认知障碍；轻度神经认知障碍；以及艾滋病相关痴呆症。
• US9278963B2
  申请人：——

  公开号：US9278963B2

  公开（公告）日：2016-03-08
• [EN] PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] COMPOSÉS DE PYRIMIDINE HYDROXY AMIDE COMME INHIBITEURS D'HISTONE DÉSACÉTYLASE
  申请人：ACETYLON PHARMACEUTICALS INC

  公开号：WO2015054474A1

  公开（公告）日：2015-04-16

  Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDACl, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDACl, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.
• PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS
  申请人：Jones Simon Stewart

  公开号：US20150105384A1

  公开（公告）日：2015-04-16

  Provided herein are compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with HDAC activity, particularly diseases or disorders that involve activity of HDAC1, HDAC2, and/or HDAC6. Also provided herein are methods for inhibiting migration of a neuroblastoma cell, inducing maturation of a neuroblastoma cell, and altering cell cycle progression of a neuroblastoma cell comprising administering to the cell a therapeutically effective amount of a HDAC1, HDAC2, and/or HDAC6 selective inhibitor or a pharmaceutically acceptable salt thereof.

  本文提供了化合物、包含这些化合物的药物组合物，以及使用这些化合物治疗或预防与HDAC活性相关的疾病或疾病的方法，特别是涉及HDAC1、HDAC2和/或HDAC6活性的疾病或疾病。本文还提供了抑制神经母细胞瘤细胞迁移、诱导神经母细胞瘤细胞成熟以及改变神经母细胞瘤细胞细胞周期进展的方法，包括向细胞施加HDAC1、HDAC2和/或HDAC6选择性抑制剂或其药用盐的治疗有效量。